Introduction {#Sec1}
============

In type 2 diabetes mellitus (T2DM), defective insulin secretion and augmented glucagon secretion contribute to glucose dysregulation \[[@CR1], [@CR2]\]. These defects are targeted by the incretin glucagon-like peptide-1 (GLP-1) \[[@CR3]\] and, therefore, GLP-1 receptor agonists (GLP-1 RAs) lower glycated hemoglobin (HbA~1c~) \[[@CR4]\]. In particular, a reduction in postprandial glucagon secretion by GLP-1 RAs may be of importance for reduced glucose excursion after a meal (postprandial glucose), which is a necessary component of improving glycemic control \[[@CR5], [@CR6]\]. However, to what extent postprandial glucagon reductions contribute to the lowering of postprandial glucose excursions in individuals with T2DM is unknown.

Lixisenatide (Lyxumia^®^, Sanofi, Paris, France), a novel GLP-1 RA \[[@CR7]\], has been shown to inhibit glucagon release \[[@CR8]\] and to markedly reduce postprandial glucagon in individuals with T2DM \[[@CR9]\]. This suggests that a reduction in glucagon may be a clinically important mechanism underlying the improved glycemic control observed following lixisenatide administration.

To examine whether reduced postprandial glucagon is of relevance for improved postprandial glucose, we examined whether the reduction in postprandial glucagon observed following treatment with lixisenatide correlates to improved glycemic outcome in two placebo-controlled Phase 3 trials (GetGoal-M \[NCT00712673\] and GetGoal-S \[NCT00713830\]). GetGoal-M assessed the efficacy of lixisenatide on glycemic control versus placebo as add-on to metformin, whereas GetGoal-S assessed lixisenatide versus placebo as add-on to sulfonylurea (SU) ± metformin \[[@CR10], [@CR11]\].

Methods {#Sec2}
=======

Overall Study Design {#Sec3}
--------------------

This analysis follows a previously published analysis that investigated the effects of lixisenatide on postprandial glucose, glucagon, and insulin after a meal test \[[@CR9]\]. Briefly, a post hoc analysis was performed of pooled data from the modified intent-to-treat populations of two of the lixisenatide Phase 3 trials---GetGoal-M and GetGoal-S.

Inclusion Criteria {#Sec4}
------------------

As reported previously \[[@CR10], [@CR11]\], GetGoal-M and GetGoal-S included patients who had T2DM for ≥1 year and HbA~1c~ levels of 7--10%. Patients in GetGoal-M were insufficiently controlled with metformin at a stable dose of ≥1.5 g per day for ≥3 months. Patients in GetGoal-S had been receiving a stable dose of an SU alone or in combination with metformin (≥1.5 g per day \[≥0.75 g per day in Japan and ≥1.0 g per day in South Korea\]) for ≥3 months. GetGoal-M and GetGoal-S were included in this post hoc analysis because these are the only studies from the GetGoal clinical trial program to assess plasma glucagon levels.

Interventions {#Sec5}
-------------

Lixisenatide 20 µg once daily or placebo was administered for 24 weeks as an add-on to metformin (GetGoal-M) or SU ± metformin (GetGoal-S). Each of these studies included a standardized meal test performed after an overnight fast. Only patients who administered lixisenatide before breakfast were included in the standardized meal test. Lixisenatide was administered exactly 30 min prior to the meal. The analysis population in the present study was the modified intent-to-treat population (all randomized and treated patients who had a baseline and post-baseline meal test assessment).

Glucagon levels were assessed during fasting and 2 h after a standardized meal test performed at baseline and at Week 24. Blood samples were drawn 30 min prior to and 2 h after a calorie-controlled breakfast (400 mL of Ensure Plus^®^, Abbott Nutrition, Columbus, OH, USA). The concentration of plasma glucagon was assessed using the Millipore/LINCO Glucagon Radioimmunoassay kit (Millipore, Billerica, MA, USA), which utilizes ^125^I-labeled glucagon and glucagon antiserum to determine the level of glucagon in plasma using the double-antibody/polyethylene glycol technique.

Outcome Measures and Statistical Analysis {#Sec6}
-----------------------------------------

For the purposes of this post hoc analysis, outcome measures at Week 24 were change from baseline in 2-h postprandial glucagon. Correlation between change from baseline in postprandial glucagon and 2-h postprandial glucose, and from baseline in postprandial glucagon and HbA~1c~ were also assessed at Week 24. Least squares mean differences between treatments in glucagon outcomes were obtained from an analysis of covariance using a linear model including treatment group, study randomization strata (HbA~1c~ \[\<8.0%, ≥8.0%\] and metformin use \[yes/no; GetGoal-S\] or body mass index \[\<30 kg/m^2^, ≥30 kg/m^2^; GetGoal-M\]) and country as fixed effects, and the corresponding baseline endpoint value as a covariate. Analyses include all patients with baseline and follow-up glucagon assessments and used the last observation carried forward values through Week 24. To control type I errors, a multiplicity adjustment was made by considering only results with a *P* value of \<0.01 as significant. To determine the correlation between glucagon and glycemic outcomes, Pearson correlation statistics were calculated for each study and combined using normalized Fisher *z*-transformed values. Results of all analyses were combined across studies using fixed-effect meta-analysis with inverse variance weights (RevMan 5.2; The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark). Linear regression modeling was performed using SAS^®^ 9.2 (SAS Institute Inc., Cary, NC, USA).

Compliance with Ethics Guidelines {#Sec7}
---------------------------------

The analysis in this article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.

Results {#Sec8}
=======

A total of 425 lixisenatide-treated patients and 176 placebo-treated patients had baseline and follow-up assessments for 2-h postprandial glucagon and were included in the analyses. Combined baseline demographics and characteristics for GetGoal-M and GetGoal-S are summarized in Table [1](#Tab1){ref-type="table"}.Table 1Overall mean baseline demographics and clinical parameters across treatment arms---safety populationsCharacteristicsLixisenatide (*n* = 425)Placebo (*n* = 176)Age, years55.7 (9.6)56.6 (10.7)Male, %44.552.3Caucasian/Asian, %94.896.6BMI, kg/m^2^31.7 (7.3)31.3 (6.9)HbA~1c~, %8.2 (0.9)8.2 (0.8)FPG, mmol/L9.5 (2.1)9.1 (2.2)Diabetes duration, years8.1 (6.1)8.8 (6.5)All values are mean (standard deviation) unless stated otherwise*BMI* body mass index, *FPG* fasting plasma glucose, *HbA* ~*1c*~ glycated hemoglobin

Glucagon Outcomes {#Sec9}
-----------------

At Week 24, mean (standard error) 2-h postprandial glucagon levels were markedly reduced from baseline in the lixisenatide arm (from 99.0 \[1.6\] to 74.9 \[1.4\] ng/L; *P* \< 0.00001) and slightly reduced in the placebo arm (from 98.8 \[2.7\] to 93.2 \[2.7\] ng/L; *P* = 0.12), resulting in significantly lower postprandial glucagon in the lixisenatide arm compared with the placebo arm at Week 24 (*P* \< 0.00001). Mean (standard error) percentage change in 2-h glucagon from baseline at Week 24 was significantly greater in the lixisenatide treatment arm versus the placebo arm (−21.3 \[1.9\] versus −1.9 \[2.4\]; *P* \< 0.00001).

Correlation Between Postprandial Glucagon and Postprandial Glucose and HbA~1c~ Levels {#Sec10}
-------------------------------------------------------------------------------------

At Week 24, least squares mean placebo-adjusted percent changes in postprandial glucose and HbA~1c~ were −33.1% and −7.7%, respectively.

Change from baseline at Week 24 in postprandial glucagon levels positively correlated with the reduction in postprandial glucose levels in patients treated with lixisenatide (*r* = 0.34; *P* \< 0.00001; Fig. [1](#Fig1){ref-type="fig"}a). There was also a weak borderline significant correlation in placebo-treated patients (*r* = 0.19; *P* = 0.01; Fig. [1](#Fig1){ref-type="fig"}a). Change from baseline in postprandial glucagon levels also positively correlated with the reduction in HbA~1c~ at Week 24 in the lixisenatide-treated patients (*r* = 0.26; *P* \< 0.00001; Fig. [1](#Fig1){ref-type="fig"}b), while no correlation was observed in the placebo-treated patients (*r* = 0.00; *P* = 0.97; Fig. [1](#Fig1){ref-type="fig"}b).Fig. 1Correlation between change in postprandial glucagon and change in **a** postprandial glucose and **b** HbA~1c~ in the lixisenatide treatment arm and the placebo arm at Week 24. *CI* Confidence interval

Discussion {#Sec11}
==========

We showed previously that lixisenatide 20 µg once daily is associated with a significant reduction from baseline to Week 24 in 2-h postprandial glucagon versus placebo in patients with T2DM insufficiently controlled on metformin and/or SU \[[@CR9]\]. The novel finding in this current report is that the reduction in postprandial glucagon in lixisenatide-treated patients positively correlates with reduced postprandial glucose and HbA~1c~ and that this is seen in patients on metformin, as well as SU.

A reduction in postprandial glucagon by lixisenatide has also been reported by Lorenz et al. in patients with T2DM treated with ≤2 oral glucose-lowering agents \[[@CR12]\] and by Meier et al. in patients administering insulin glargine ± metformin \[[@CR13]\]. This shows that one of the mechanisms of lixisenatide in T2DM is to reduce postprandial glucagon. The data described herein suggest that this effect may contribute to the lowering of blood glucose concentrations, as demonstrated by the direct positive correlation of 2-h glucagon reductions with decreases in postprandial glucose and HbA~1c~. Such an effect may be achieved by a reduction in hepatic glucose production by the lowering of glucagon, as it is known that there is a linear relationship between portal glucagon levels and hepatic glucose production \[[@CR14]\]. Hence, a reduction in glucagon may play an important role in improved glycemic control following lixisenatide administration. However, since these studies were neither designed nor powered to demonstrate the causality between the two effects, this post hoc analysis focused on correlation only. There was a slight, although significant, reduction in postprandial glucose in the placebo group, which was positively correlated with change in glucagon. The correlation was marginally significant, possibly due to the relatively small sample size. However, there was no evidence of correlation between change in HbA~1c~ and change in glucagon in the placebo group. Interestingly, a recent study by Kramer et al. has reported that chronic liraglutide treatment is associated with a paradoxical enhancement in hyperglucagonemia, which emerged 12 weeks after treatment initiation and persists over a 48-week treatment period, together with sustained glycemic control. The authors suggest that the glucose-lowering effects of liraglutide may not be due to the postprandial reduction in glucagon that is observed with short-term treatment, speculating that long-term benefits may be due to α-cell compensation \[[@CR15]\].

The mechanism underlying the reduction in postprandial glucagon by lixisenatide was not established in this post hoc analysis of two Phase 3 studies. Two important mechanisms may, however, be involved. One mechanism is the direct inhibition of glucagon secretion from the islets, which is a well-known effect of GLP-1 \[[@CR3], [@CR4]\], and is also observed with lixisenatide \[[@CR8]\]. Another mechanism is an indirect effect through delayed gastric emptying. A delay in gastric emptying is a well-known effect of lixisenatide \[[@CR12], [@CR13]\] and results in diminished nutrient appearance in the circulation, thereby reducing the stimulation of islet function. Such a mechanism may also explain the reduction in 2-h postprandial insulin following lixisenatide administration \[[@CR9]\], as demonstrated previously following exenatide twice-daily treatment \[[@CR16]\].

The data described herein contribute to our understanding of how lixisenatide provides glycemic control in patients with T2DM; however, certain limitations should be acknowledged. First, the populations included in the two studies forming the basis of this post hoc analysis showed some differences in that patients in GetGoal-M had a higher body mass index than those in GetGoal-S, whereas GetGoal-S included a higher number of patients from Asia and patients with a longer duration of T2DM. Further investigations may address whether this heterogeneity is of importance for treatment with lixisenatide. Second, the current study does not provide any insight into the relative contribution of lixisenatide in the suppression of gastric emptying or the direct effect of lixisenatide on specific islet cells; this needs to be addressed in future mechanistic studies.

Conclusion {#Sec12}
==========

In conclusion, this post hoc analysis suggests that the reduction of postprandial glucagon by lixisenatide contributes to reduced postprandial glucose and HbA~1c~ in patients with T2DM insufficiently controlled on metformin and/or SU.
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